Anne Grunenwald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Grunenwald has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Lubka Roumenina
INSERM
4 shared publications Julie Peliconi
Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Institut National Inflammation Complement and Cancer team Inserm INSERM UMRS1138 Cordeliers Research Center Hoffmann-La Roche de la Santé et de la Recherche Médicale Sorbonne Université Université de Paris Cité Paris France
2 shared publications- Alessandra Zarantonello
Centre de Recherche des Cordeliers
1 shared publication Alexandre Hertig
Department of Nephrology, Poissy Hospital, Poissy, France
1 shared publicationCamille Brochier
Institut Roche Boulogne Billancourt France
1 shared publication- Christophe Bontoux
Department of Pathology, Cancer University Institute of Toulouse-Oncopole, University Hospital of Toulouse, 1 av Irène Joliot-Curie, Toulouse, 31059, France
1 shared publication
Latest Publications
- Open Access
- 14 October 2025
- Published by Springer Nature in Research Square
Transcriptomic atlas reveals inflammation and complement as pathogenic factors in hemolysis-induced tissue damage
Intravascular hemolysis contributes to sickle cell disease (SCD) by releasing danger signals like hemoglobin and heme, which trigger inflammation and oxidative stress. Yet, the exact mechanisms behind organ damage remain unclear. Using bulk RNA sequencing in a phenylhydrazine-induced hemolysis model in mice, we mapped transcriptional changes across the spleen, liver, lung, and kidney. We identified common gene expression patterns tied to inflammation, oxidative stress, cell death, coagulation, and metabolic reprogramming. These signatures appeared consistently in SCD (HbSS Townes mice), heme-injected mice, and phenylhydrazine-treated mice, implicating heme as a shared driver of injury. Complement activation emerged as a central mechanism, marked by elevated plasma C5a and increased C5aR1 expression in all organs. Notably, C5 inhibition reduced inflammatory gene expression, especially in the lung. Our findings highlight inflammation and complement activation as key mediators of hemolysis-induced organ injury and point to complement inhibition as a potential therapy. This study sheds light on the broader impact of hemolysis in SCD, including complications like acute chest syndrome and organ dysfunction.
- 14 October 2025
- Published by Springer Nature in Research Square
Open AccessTranscriptomic atlas reveals inflammation and complement as pathogenic factors in hemolysis-induced tissue damage
Intravascular hemolysis contributes to sickle cell disease (SCD) by releasing danger signals like hemoglobin and heme, which trigger inflammation and oxidative stress. Yet, the exact mechanisms behind organ damage remain unclear. Using bulk RNA sequencing in a phenylhydrazine-induced hemolysis model in mice, we mapped transcriptional changes across the spleen, liver, lung, and kidney. We identified common gene expression patterns tied to inflammation, oxidative stress, cell death, coagulation, and metabolic reprogramming. These signatures appeared consistently in SCD (HbSS Townes mice), heme-injected mice, and phenylhydrazine-treated mice, implicating heme as a shared driver of injury. Complement activation emerged as a central mechanism, marked by elevated plasma C5a and increased C5aR1 expression in all organs. Notably, C5 inhibition reduced inflammatory gene expression, especially in the lung. Our findings highlight inflammation and complement activation as key mediators of hemolysis-induced organ injury and point to complement inhibition as a potential therapy. This study sheds light on the broader impact of hemolysis in SCD, including complications like acute chest syndrome and organ dysfunction.
- Open Access
- 29 August 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (17) , 4458-4469
HCAR2 is a novel receptor for heme
Extracellular heme, released during intravascular hemolysis in sickle cell disease (SCD) and hemolytic anemia, acts as a proinflammatory danger signal, requiring robust defense mechanisms. Previous studies identified G protein–coupled receptor (GPCR) signaling triggered by heme, but the specific receptor remained unknown. Transcriptomic analysis of bulk RNA sequencing of liver tissues from SCD and hemolytic mice (injection of phenylhydrazine) revealed GPCR signaling as a commonly enriched pathway. Unbiased screening of 241 GPCRs identified Hydroxycarboxylic Acid Receptor 2 (HCAR2/GPR109A), an anti-inflammatory receptor for niacin, as a novel heme sensor. Heme binding to human HCAR2 was validated using a functional reporter cell assay and direct interaction analyses via surface plasmon resonance and absorbance spectroscopy. In vivo, HCAR2 was upregulated in the liver of SCD and hemolytic mice, paralleling the expression of the heme-degrading enzyme heme oxygenase-1 (HO-1). HO-1 inhibition or heme injection further increased HCAR2 expression, indicating that heme acts as both a ligand and an inducer of HCAR2. These findings identify HCAR2 as a novel heme receptor and reveal a heme–HCAR2–HO-1 negative feedback loop involved in tissue protection in hemolytic diseases.
- 29 August 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (17) , 4458-4469
Open AccessHCAR2 is a novel receptor for heme
Extracellular heme, released during intravascular hemolysis in sickle cell disease (SCD) and hemolytic anemia, acts as a proinflammatory danger signal, requiring robust defense mechanisms. Previous studies identified G protein–coupled receptor (GPCR) signaling triggered by heme, but the specific receptor remained unknown. Transcriptomic analysis of bulk RNA sequencing of liver tissues from SCD and hemolytic mice (injection of phenylhydrazine) revealed GPCR signaling as a commonly enriched pathway. Unbiased screening of 241 GPCRs identified Hydroxycarboxylic Acid Receptor 2 (HCAR2/GPR109A), an anti-inflammatory receptor for niacin, as a novel heme sensor. Heme binding to human HCAR2 was validated using a functional reporter cell assay and direct interaction analyses via surface plasmon resonance and absorbance spectroscopy. In vivo, HCAR2 was upregulated in the liver of SCD and hemolytic mice, paralleling the expression of the heme-degrading enzyme heme oxygenase-1 (HO-1). HO-1 inhibition or heme injection further increased HCAR2 expression, indicating that heme acts as both a ligand and an inducer of HCAR2. These findings identify HCAR2 as a novel heme receptor and reveal a heme–HCAR2–HO-1 negative feedback loop involved in tissue protection in hemolytic diseases.
- 23 August 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (1) , 289-291
A hot bath a day does not keep the nephrologist away
- 23 August 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (1) , 289-291
A hot bath a day does not keep the nephrologist away
- Open Access
- 5 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (7) , 1205-1217
De novo thrombotic microangiopathy after kidney transplantation in adults: Interplay between complement genetics and multiple endothelial injury
- 5 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (7) , 1205-1217
Open AccessDe novo thrombotic microangiopathy after kidney transplantation in adults: Interplay between complement genetics and multiple endothelial injury
- 14 November 2023
- Published by Elsevier in La Presse Médicale
- Vol. 52 (4) , 104205
Complement involvement in sickle cell disease
- 14 November 2023
- Published by Elsevier in La Presse Médicale
- Vol. 52 (4) , 104205
Complement involvement in sickle cell disease
- Open Access
- 18 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (4) , 2009
Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases
The incidence of kidney disease is rising, constituting a significant burden on the healthcare system and making identification of new therapeutic targets increasingly urgent. The heme oxygenase (HO) system performs an important function in the regulation of oxidative stress and inflammation and, via these mechanisms, is thought to play a role in the prevention of non-specific injuries following acute renal failure or resulting from chronic kidney disease. The expression of HO-1 is strongly inducible by a wide range of stimuli in the kidney, consequent to the kidney’s filtration role which means HO-1 is exposed to a wide range of endogenous and exogenous molecules, and it has been shown to be protective in a variety of nephropathological animal models. Interestingly, the positive effect of HO-1 occurs in both hemolysis- and rhabdomyolysis-dominated diseases, where the kidney is extensively exposed to heme (a major HO-1 inducer), as well as in non-heme-dependent diseases such as hypertension, diabetic nephropathy or progression to end-stage renal disease. This highlights the complexity of HO-1’s functions, which is also illustrated by the fact that, despite the abundance of preclinical data, no drug targeting HO-1 has so far been translated into clinical use. The objective of this review is to assess current knowledge relating HO-1’s role in the kidney and its potential interest as a nephroprotection agent. The potential therapeutic openings will be presented, in particular through the identification of clinical trials targeting this enzyme or its products.
- 18 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (4) , 2009
Open AccessHeme Oxygenase 1: A Defensive Mediator in Kidney Diseases
The incidence of kidney disease is rising, constituting a significant burden on the healthcare system and making identification of new therapeutic targets increasingly urgent. The heme oxygenase (HO) system performs an important function in the regulation of oxidative stress and inflammation and, via these mechanisms, is thought to play a role in the prevention of non-specific injuries following acute renal failure or resulting from chronic kidney disease. The expression of HO-1 is strongly inducible by a wide range of stimuli in the kidney, consequent to the kidney’s filtration role which means HO-1 is exposed to a wide range of endogenous and exogenous molecules, and it has been shown to be protective in a variety of nephropathological animal models. Interestingly, the positive effect of HO-1 occurs in both hemolysis- and rhabdomyolysis-dominated diseases, where the kidney is extensively exposed to heme (a major HO-1 inducer), as well as in non-heme-dependent diseases such as hypertension, diabetic nephropathy or progression to end-stage renal disease. This highlights the complexity of HO-1’s functions, which is also illustrated by the fact that, despite the abundance of preclinical data, no drug targeting HO-1 has so far been translated into clinical use. The objective of this review is to assess current knowledge relating HO-1’s role in the kidney and its potential interest as a nephroprotection agent. The potential therapeutic openings will be presented, in particular through the identification of clinical trials targeting this enzyme or its products.